Moderna MRNA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Contract with Customer, Liability by Product | ||||||
| Net product sales | $567M-9.4% | $626M-11.5% | $707M-29.7% | $1.01B-34.0% | $1.53B-21.8% | |
| Other revenue | $544M+32.0% | $412M+42.1% | $290M— | —— | —— | |
| Total Revenue by Product | ||||||
| Collaboration Arrangement, Including Arrangements With Affiliate | $17M+30.8% | $13M-48.0% | $25M-45.7% | $46M-6.1% | $49M+2.1% | |
| Grant revenue | $21M-4.5% | $22M-26.7% | $30M+30.4% | $23M-88.1% | $194M+0.5% | |
| Licensing and royalty revenue | $4M-66.7% | $12M-29.4% | $17M-22.7% | $22M-56.0% | $50M+19.0% | |
| Additions by Product | ||||||
| Net product sales | $108M0.0% | $108M+27.1% | $85M-24.8% | $113M-46.4% | $211M-6.2% | |
| Other revenue | $251M+18.4% | $212M— | —— | —— | —— | |
| Contract With Customer, Liability, Deductions During Period by Product | ||||||
| Net product sales | $167M-11.6% | $189M-50.8% | $384M-39.2% | $632M-0.8% | $637M-2.0% | |
| Other revenue | $119M+32.2% | $90M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Moderna break its business down?
- Moderna (MRNA) reports contract with customer, liability by product across 2 parts — Net product sales and Other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Moderna's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Moderna's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
